(MGNX) MacroGenics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MGNX) MacroGenics, Inc. Complete Analysis Pack
Validate Every Claim with the Complete Sources File
This MacroGenics, Inc. SWOT Analysis gives a concise, company-specific view of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the page includes a real preview/sample of the analysis so you can assess style and substance before buying. Purchase the full version to download the complete, ready-to-use SWOT report.
Strengths
1 approved product MARGENZA
MacroGenics, Inc. has one approved product, MARGENZA, so it has a real commercial foothold in targeted oncology. The drug is approved with chemotherapy for adult patients with metastatic HER2-positive breast cancer after at least 2 prior anti-HER2 regimens, giving MacroGenics, Inc. access to a high-need, specialty market. This single approval is a key strength because it validates the platform and keeps the company in the marketed-drug segment.
11 named investigational programs
MacroGenics, Inc.'s 11 named investigational programs give it unusually broad pipeline depth: MGC018, enoblituzumab, MGD024, lorigerlimab, tebotelimab, retifanlimab, IMGC936, MGD014, MGD020, teplizumab, and PRV-3279. That spread lowers single-asset clinical risk and gives the Company more shots at future approvals. It also matters financially, because one program setback is less likely to derail the whole portfolio.
Multiple modalities ADCs mAbs DARTs
MacroGenics, Inc.'s platform spans ADCs, monoclonal antibodies, bispecifics, and DART molecules, giving it more shots on goal across oncology and beyond. That breadth supports programs in solid tumors, hematologic cancers, HIV, diabetes, and autoimmune disease, so one setback is less likely to hit the whole pipeline. In 2025, MacroGenics, Inc. still had multiple clinical-stage assets, which shows real pipeline depth.
4 named collaboration partners
MacroGenics, Inc. has 4 named collaboration partners: Incyte, Zai Lab, I-Mab, and Janssen Biotech. These deals can bring outside funding, shared development costs, and broader market reach, which matters for a company that reported $76.4 million in revenue in 2024. The partnerships also support its antibody-engineering credibility.
- 4 strategic partners
- Funding plus development support
- Better market access
- Stronger platform validation
Founded in 2000 Rockville Maryland
Founded in 2000, MacroGenics has been in operation for 26 years as of 2026, which supports scientific continuity and long-term industry ties. Its headquarters in Rockville, Maryland keeps the Company close to the U.S. biotech corridor, where talent, partners, and capital are easier to access. That long base also helps it keep know-how across drug programs and partnerships.
- 26 years of operating history in 2026
- Headquartered in Rockville, Maryland
- Supports scientific continuity
- Helps sustain industry relationships
MacroGenics: Approved Drug, 11-Program Pipeline, and Real Revenue
MacroGenics, Inc.'s key strengths are its approved drug MARGENZA, a broad 11-program pipeline, and a multi-modal platform across ADCs, antibodies, bispecifics, and DART molecules. In 2025, the Company also kept 4 named partners and reported $76.4 million revenue in 2024, showing commercial traction and outside validation.
| Strength | Data point |
|---|---|
| Approved product | MARGENZA |
| Pipeline size | 11 named programs |
| Strategic partners | 4 |
| Revenue | $76.4 million in 2024 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing MacroGenics, Inc.’s business strategy
Editable Excel File
Provides a quick MacroGenics SWOT snapshot to simplify strategy review and decision-making.
Reference Sources
Provides a concise, traceable sources list linking MacroGenics claims to industry reports, clinical registries, and regulatory filings for faster due diligence and verifiable assumptions.
Weaknesses
1 approved product only
MacroGenics has a very limited commercial base because MARGENZA is still its only marketed product. That means revenue depends on one asset, so any slowdown in prescriptions, pricing, or partner sales can hit results hard. With no second approved product to balance cash flow, the Company’s growth and margin profile stay exposed to single-product risk.
Narrow approved label HER2-positive breast cancer
MacroGenics, Inc.'s approved use is still narrow: it targets metastatic HER2-positive breast cancer after at least 2 prior anti-HER2 regimens. That limits the treatable pool versus broader oncology labels, so near-term sales scaling is capped. It also leaves MacroGenics, Inc. more exposed to uptake swings in a small, heavily treated subgroup.
11 programs mostly investigational
MacroGenics still has 11 programs mostly in clinical or investigational stages, so most of its value is tied to future approvals, not current sales. Clinical-stage assets do not generate product revenue until approval and launch, and development can still take years with high trial risk. That leaves earnings exposed to delays, study failures, and heavier R&D spending before any cash flow starts.
Oncology-heavy portfolio mix
MacroGenics, Inc. leans heavily on oncology, and most named assets target cancer. That leaves the company exposed to one of pharma’s most crowded fields, where rivals spend billions on similar targets. It also raises clinical risk: oncology programs have some of the highest failure rates in drug development, often above 90% before approval.
- High cancer-pipeline concentration
- Intense oncology competition
- Very high clinical attrition
Partner reliance for scale
MacroGenics, Inc. relies on outside partners to move parts of its pipeline forward, so scale is not fully under its own control. That can help share development cost, but it also leaves timing, trial execution, and next steps exposed to partner priorities.
- Partner delays can slow program progress.
- External control can weaken launch timing.
- Shared scale can cap internal flexibility.
MacroGenics’ Weak Point: One Drug, Narrow Label, Heavy Pipeline Risk
MacroGenics remains weak because MARGENZA is still its only marketed drug, so one product drives revenue and any slip in demand hits results fast. Its label is narrow in metastatic HER2-positive breast cancer, which caps the addressable pool. Most of the 11 programs are still clinical, so cash burn stays high and approvals are uncertain.
| Weakness | Data |
|---|---|
| Marketed products | 1 |
| Pipeline programs | 11 |
| Lead label | Metastatic HER2-positive breast cancer |
Preview the Actual Deliverable
MacroGenics, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.
Opportunities
11 pipeline shots at approval
MacroGenics has 11 pipeline shots at approval across multiple oncology settings, giving it several chances to create new revenue streams. Even one late-stage win could be material for a company with 2025 revenue of about $0.1B and a much smaller base. That kind of success could change the scale of the business fast.
B7-H3 assets MGC018 and enoblituzumab
B7-H3 is a key tumor target in MacroGenics, Inc.'s pipeline, with 2 programs aimed at the same biology: MGC018, an antibody-drug conjugate, and enoblituzumab, a monoclonal antibody. This gives MacroGenics, Inc. 2 shots at solid tumors that often resist older targets.
If either asset shows stronger clinical data, the addressable market could widen beyond niche settings into larger solid-tumor groups. That matters because B7-H3 is seen across many cancers, so positive readouts can raise partnering and value-creation odds.
PD-1 CD123 and LAG-3 combinations
MacroGenics, Inc. has 3 immune-oncology shots in play: MGD024, lorigerlimab, and tebotelimab. These programs hit validated checkpoints like PD-1 and LAG-3, while CD123 gives access to hematologic cancers. Combination and multispecific designs can widen use and raise response depth; in FY2025, that matters as a capital-light way to extend pipeline value.
Beyond oncology teplizumab and PRV-3279
MacroGenics’ non-oncology programs, including type 1 diabetes and autoimmune disease assets such as teplizumab and PRV-3279, widen its reach beyond cancer and into larger adjacent markets. That matters because autoimmune disease affects tens of millions of people in the U.S. alone, so even one successful launch could add a new revenue stream and reduce reliance on oncology.
- Expands beyond cancer
- Targets high-value autoimmune markets
- Diversifies future revenue
Global partners Incyte Zai Lab I-Mab Janssen
MacroGenics’ partner base with Incyte, Zai Lab, I-Mab and Janssen can widen development reach and speed regional expansion without MacroGenics funding every step. Existing alliances also lower cash strain, since partners can absorb part of the cost for trials, regulatory work and local commercialization.
- 4 active global partners
- Broader regional access
- Shared trial and launch costs
- Lower capital burden
These networks matter most for assets that need local expertise in China, oncology and specialty indications, where partner execution can add speed and reduce risk. For a smaller biotech, that can preserve cash for core programs while keeping more shots on goal.
MacroGenics’ 11 Pipeline Shots Could Unlock Big Upside
MacroGenics, Inc.’s main upside is pipeline breadth: 11 shots at approval across oncology and immune disease. With FY2025 revenue near $0.1B, even one late-stage win could matter a lot. B7-H3, PD-1/LAG-3, and CD123 give several paths to value.
| Opportunity | FY2025 data |
|---|---|
| Pipeline shots | 11 |
| Revenue | ~$0.1B |
| Active partners | 4 |
Threats
Clinical attrition risk across 11 programs
MacroGenics, Inc. is exposed to high clinical attrition risk across 11 investigational programs, so one late-stage miss can erase a major future value driver. Biopharma failure rates stay high; industry studies often show only about 1 in 10 drug candidates entering clinical testing reach approval. That makes each readout critical for valuation and cash planning.
Crowded HER2 ADC and immuno-oncology markets
MacroGenics, Inc. faces a crowded HER2 ADC and immuno-oncology field, where MARGENZA and pipeline assets compete with larger, better-funded rivals. AbbVie said it would buy ImmunoGen for $10.1 billion in 2024, showing how much capital flows into HER2 ADCs. Strong HER2, B7-H3, CD123, PD-1, and LAG-3 programs can still squeeze share and weaken partnering leverage.
Regulatory approval uncertainty
MacroGenics, Inc. faces real approval risk because investigational biologics must clear FDA safety and efficacy tests, and complex mechanisms can trigger unexpected toxicity or weak tumor response.
That matters in a market where only 14 of 61 oncology drugs got FDA approval in 2024, or 23%, so even late-stage assets can miss the bar.
Any delay can extend burn, and MacroGenics, Inc. had to fund long trials before revenue can scale.
Commercial pressure on MARGENZA
MARGENZA is MacroGenics, Inc.'s only approved product, and its use is limited to a narrow HER2-positive metastatic breast cancer group after prior anti-HER2 therapy. That makes sales sensitive to competitor drugs, how doctors sequence treatment, and slow adoption in a small addressable market. If MARGENZA uptake stalls, MacroGenics, Inc. has little other commercial cushion.
- MARGENZA is the only approved product.
- Target market is small and tightly defined.
- Adoption risk can hit all company sales.
Funding and execution dependence
MacroGenics’ pipeline depends on steady cash and partner delivery, and drug development can cost $50 million to $200 million per Phase 3 program. If financing tightens or collaborators slip, trial timing, filing plans, and launch readiness can all slow at once.
- High R&D burn needs fresh capital
- Partner delays can stall milestones
- Weak markets pressure program pace
MacroGenics Faces Big Pipeline and FDA Risk
MacroGenics, Inc. still faces high trial failure risk across 11 programs, and MARGENZA is the only approved product. That leaves valuation tied to a few readouts, with one miss able to hit cash, milestones, and partner interest fast.
Competition is also fierce in HER2 ADC and immuno-oncology, while FDA approval risk stays high; in 2024, only 14 of 61 oncology drugs won FDA approval.
| Threat | Data point |
|---|---|
| Pipeline risk | 11 programs |
| Commercial risk | 1 approved product |
| Regulatory risk | 14 of 61 oncology approvals in 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.